# Pizarra — PT-pseudo_d38917f87b35 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d38917f87b35
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 28.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: -0.78 ng/mL/yr
  - Prior PSA: 25.3 ng/mL
  - Prostate volume: 70.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8709831 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia
  - Current medication: empagliflozin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.

Vitals: weight 99 kg, height 177 cm, BMI 31.6, BP 126/68 mmHg, HR 67 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2015).

Chief complaint: Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review.

History: A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable.

Patient info: retired firefighter; Widowed; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 12 units / week; exercise Running 3x/week, 5 km; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.42 +/- 0.20   (95% CI 0.08-0.82)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 5.9 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=28.3, age=61.0, psad=0.4, dre_ord=1.0, vol=70.0, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (-0.78 ng/mL/yr) or the full context of the mpMRI report (beyond the PI-RADS 5 score) or the specific details from the laboratory panel.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide uncertainty interval (0.42 +/- 0.20). This wide interval suggests the input features are highly ambiguous for the model. Specifically, the prior fails to account for the high csPCa predicted probability (0.8709831) combined with a high PI-RADS score of 5, which strongly contradicts the 'NO BIOPSY' suggestion. Furthermore, the prior ignores the history of a prior positive biopsy (ISUP GG5), which fundamentally changes the question from "Does he have cancer?" to "Is the cancer progressing/recurrent?"

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> What is the full prose of the mpMRI report? -> A more detailed description of the lesion characteristics could refine the PI-RADS 5 interpretation.
  <document> PSA history (trend) -> What is the full PSA trend/velocity history? -> A more detailed trend might confirm if the rise is concerning given the prior positive result.
  <document> previous GP / urology consultation notes -> What are the details from previous notes? -> These notes might contain context regarding the prior biopsy findings or LUTS severity.
  <document> laboratory results (full panel) -> What are the full laboratory results? -> This could provide context on other markers that might influence the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_d38917f87b35", "radiology_report": "Radboudumc Radiology Service | 08 Jan 2025\nStudy: Multiparametric MRI of the Prostate\nIndication: Follow-up after a previously positive biopsy. Current prostate-specific antigen stands at 28.3.\n\nFindings: The gland occupies a total volume of 70.0 mL. A discrete abnormality localizes to the left peripheral zone, spanning the base through mid-gland, measuring roughly 28 mm longest diameter. T2 sequences highlight pronounced hypointensity within this focus. Diffusion-weighted techniques demonstrate marked restriction, mirrored by low apparent diffusion coefficient values. Post-contrast phases show prompt, localized enhancement compared to adjacent tissue. Seminal vesicles appear normal and symmetrical. Pelvic lymph nodes show no suspicious morphology, and capsular integrity remains intact without extracapsular spread.\n\nImpression: Left peripheral zone mass scoring PI-RADS 5. Calculated PSA density registers 0.4. Estimated csPCa probability computes to 0.8709831."}
  
  **psa_trend**
  {"case_id": "PT-pseudo_d38917f87b35", "psa_trend": [{"date": "Jul 2023", "val": 1.3}, {"date": "Dec 2023", "val": 19.1}, {"date": "Apr 2024", "val": 9.0}, {"date": "Aug 2024", "val": 9.7}, {"date": "Jan 2025", "val": 28.3}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_d38917f87b35", "previous_notes": [{"date": "16 May 2024", "author": "Dr. R. van den Berg (GP)", "text": "An April 2024 PSA draw returned 23.1 ng/mL, continuing the rising trend established since the initial biopsy confirmed a Positive result earlier in the calendar year. Clinical tracking focused on lower urinary tract symptom progression and overall health status."}, {"date": "17 Jan 2024", "author": "Dr. R. van den Berg (GP)", "text": "Following a December 2023 PSA measurement of 22.4 ng/mL, a consultation addressed the recent prostate cancer diagnosis and the significance of the earlier biopsy results. Discussion centered on the pathological features and general prognosis. Scheduled laboratory assessments and symptom tracking continued."}]}
  
  **laboratory_results**
  {"case_id": "PT-pseudo_d38917f87b35", "laboratory_results": [{"name": "PSA", "val": "28.3 ng/mL", "date": "02 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.22 ng/mL", "date": "02 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "11%", "date": "02 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "13.8 g/dL", "date": "02 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.2 x10^9/L", "date": "02 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "244 x10^9/L", "date": "02 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "90 umol/L", "date": "02 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "02 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "15.8 nmol/L", "date": "02 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "93 U/L", "date": "02 Dec 2024", "flag": ""}, {"name": "LDH", "val": "150 U/L", "date": "02 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision point, as per the tool description.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  Left peripheral zone mass scoring PI-RADS 5.
  csPCa predicted probability: 0.8709831.
  PSA velocity: -0.78 ng/mL/yr (Note: The trend shows a significant rise from 9.7 to 28.3 ng/mL over ~1 year).
  Prior biopsy result: Positive (ISUP GG5 disease).
  
  AGAINST sampling this patient now:
  %Free PSA: 11% (This is often used to argue against biopsy in low-risk scenarios, though context is needed).

WHERE THIS LEANS
  The evidence strongly argues FOR sampling due to the high-risk imaging features (PI-RADS 5, high csPCa probability) and the concerning PSA trajectory following a prior positive diagnosis. This contradicts the statistical prior of 'NO BIOPSY'.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the patient presents with a high-risk finding (PI-RADS 5) and a high predicted cancer probability (csPCa 0.8709831). This is strongly supported by the concerning PSA trajectory, which shows a significant rise to 28.3 ng/mL following a prior positive biopsy (ISUP GG5). The evidence converges on the need for further tissue sampling to assess progression or recurrence.

Variables that carried weight: bx=decisive, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
